Singapore markets closed

Innate Pharma S.A. (IPHA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
2.8800+0.5100 (+21.52%)
At close: 04:00PM EDT
2.8800 0.00 (0.00%)
After hours: 04:57PM EDT

Innate Pharma S.A.

117, Avenue de Luminy
BP 30191
Marseille 13009
France
33 4 30 30 30 30
https://www.innate-pharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees

Key executives

NameTitlePayExercisedYear born
Dr. Herve Brailly Ph.D.Co-Founder, Interim CEO & Chairman of Executive BoardN/AN/A1961
Mr. Yannis Morel Ph.D.Executive VP, COO & Member of Executive Board403.79kN/A1973
Dr. François Romagné Ph.D.FounderN/AN/A1964
Mr. Eric Vivier D.V.M., M.B.A., Ph.D.Founder, Senior VP & Chief Scientific OfficerN/AN/A1964
Dr. Marc Bonneville Ph.D.FounderN/AN/A1960
Mr. Jean Jacques Fournié Ph.D.FounderN/AN/AN/A
Mr. Alessandro Moretta M.D., Ph.D.FounderN/AN/AN/A
Mr. Frederic Lombard M.B.A.Senior VP & CFON/AN/A1975
Dr. Sonia Quaratino M.D., Ph.D.Executive VP, Chief Medical Officer & Member of Executive BoardN/AN/A1962
Mr. Arvind SoodExecutive VP, President of US Operations & Member of Executive BoardN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), an Anti-C5aR Antibody; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH4501, an antibody drug conjugates (ADC); and IPH65, a tetra-specific proprietary antibody. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

Corporate governance

Innate Pharma S.A.’s ISS governance QualityScore as of 1 March 2024 is 9. The pillar scores are Audit: 8; Board: 9; Shareholder rights: 4; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.